Unknown PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT04679038

A Trial of SHR-1701 in Combination With Famitinib in Patients With Advanced Solid Tumors

SHR-1701 Plus Famitinib Malate in Advanced Solid Tumors: An Open-label, Multi-center, Phase I/II Trial

Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Updated 5 times since 2021 Last updated: Jan 11, 2022 Started: Mar 17, 2021 Primary completion: Dec 1, 2022 Completion: Oct 1, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1/PHASE2 clinical study on Solid Tumor, this trial is ongoing. The trial is conducted by Jiangsu HengRui Medicine Co., Ltd. and has accumulated 5 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1/PHASE2

Status: Unknown Status → Unknown · Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Feb 2024 — Jul 2024 [monthly]

Unknown Status PHASE1_PHASE2

Status: Recruiting → Unknown Status
Feb 2022 — Feb 2024 [monthly]

Recruiting PHASE1_PHASE2

Status: Not Yet Recruiting → Recruiting
Jan 2021 — Feb 2022 [monthly]

Not Yet Recruiting PHASE1_PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jiangsu HengRui Medicine Co., Ltd.

Data source: Jiangsu HengRui Medicine Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Beijing, China , Changsha, China , Gannan, China , Hangzhou, China , Harbin, China , Hefei, China , Jinan, China , Nanjing, China , Qingdao, China , Shanghai, China and 3 more locations